Something that sets Lexeo Therapeutics apart from a lot of other gene therapy firms, as highlighted by CEO R. Nolan...
Lexeo’s Approach To Gene Therapy For Common Conditions
CEO Expects First Commercial Launch As Early As 2026
Since becoming CEO of Lexeo a year before its launch, R. Nolan Townsend has steered the company from strength to strength, expanding its pipeline from three to eight novel therapeutics and ultimately developing therapeutics for a future where gene therapy can cut healthcare costs.
